Parallel Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.5M Buy
16,366
+3,742
+30% +$574K 0.05% 259
2025
Q4
$1.74M Buy
12,624
+148
+1% +$19.4K 0.03% 318
2025
Q3
$1.6M Buy
12,476
+351
+3% +$42.8K 0.03% 324
2025
Q2
$1.47M Sell
12,125
-706
-6% -$79.6K 0.03% 329
2025
Q1
$1.43M Sell
12,831
-1,586
-11% -$169K 0.03% 323
2024
Q4
$1.4M Buy
14,417
+496
+4% +$52.9K 0.03% 314
2024
Q3
$1.6M Buy
13,921
+975
+8% +$111K 0.04% 284
2024
Q2
$1.38M Buy
12,946
+896
+7% +$89.9K 0.04% 292
2024
Q1
$1.17M Buy
12,050
+3,179
+36% +$326K 0.03% 331
2023
Q4
$896K Sell
8,871
-235
-3% -$22.7K 0.03% 359
2023
Q3
$928K Buy
9,106
+298
+3% +$30.2K 0.03% 326
2023
Q2
$889K Buy
8,808
+762
+9% +$76.2K 0.03% 338
2023
Q1
$740K Buy
8,046
+705
+10% +$61.6K 0.03% 369
2022
Q4
$666K Sell
7,341
-63
-0.9% -$5.31K 0.03% 339
2022
Q3
$563K Sell
7,404
-771
-9% -$63.9K 0.03% 359
2022
Q2
$691K Sell
8,175
-2,138
-21% -$188K 0.03% 314
2022
Q1
$907K Sell
10,313
-1,684
-14% -$146K 0.04% 288
2021
Q4
$1.05M Sell
11,997
-1,900
-14% -$158K 0.04% 261
2021
Q3
$1.14M Buy
13,897
+2,123
+18% +$191K 0.05% 240
2021
Q2
$1.07M Buy
11,774
+3,484
+42% +$310K 0.05% 244
2021
Q1
$709K Buy
8,290
+486
+6% +$43.6K 0.03% 291
2020
Q4
$737K Buy
7,804
+157
+2% +$13.7K 0.04% 257
2020
Q3
$665K Buy
7,647
+834
+12% +$72.3K 0.04% 248
2020
Q2
$595K Buy
6,813
+1,438
+27% +$124K 0.04% 262
2020
Q1
$443K Sell
5,375
-1,338
-20% -$119K 0.04% 273
2019
Q4
$636K Buy
6,713
+65
+1% +$5.83K 0.05% 249
2019
Q3
$578K Buy
6,648
+1,603
+32% +$144K 0.05% 246
2019
Q2
$461K Sell
5,045
-468
-8% -$39.6K 0.05% 254
2019
Q1
$475K Buy
5,513
+1,561
+39% +$125K 0.05% 225
2018
Q4
$303K Buy
3,952
+747
+23% +$58.1K 0.04% 275
2018
Q3
$247K Buy
3,205
+65
+2% +$4.8K 0.03% 341
2018
Q2
$212K Sell
3,140
-1,166
-27% -$80.5K 0.03% 337
2018
Q1
$312K Buy
4,306
+130
+3% +$9.9K 0.05% 245
2017
Q4
$314K Buy
4,176
+62
+2% +$4.68K 0.05% 244
2017
Q3
$305K Buy
4,114
+14
+0.3% +$1.06K 0.05% 248
2017
Q2
$313K Buy
4,100
+511
+14% +$36.2K 0.06% 242
2017
Q1
$250K Sell
3,589
-1,017
-22% -$67.8K 0.05% 257
2016
Q4
$301K Buy
+4,606
New +$299K 0.07% 192

Other funds holding NVS

Parallel Advisors's NVS Position: Q1 2026 in Review

Parallel Advisors increased its Novartis (NVS) stake by 30% in Q1 2026, buying an estimated $574K and bringing the position to 16,366 shares worth $2.5M. The position accounts for 0.05% of the portfolio, ranked #259.

Parallel Advisors first reported a position in NVS in Q4 2016 and has held it in 38 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Parallel Advisors held 16,366 shares of Novartis worth $2.5M as of Q1 2026.
  • Parallel Advisors bought 3,742 Novartis shares in Q1 2026, an estimated $574K.
  • Novartis made up 0.05% of Parallel Advisors's portfolio in Q1 2026, its #259 holding.
  • Parallel Advisors first reported a position in Novartis in Q4 2016 and has held it in 38 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.